Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,131 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

NCT05551936

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, not recruiting

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

NCT03580928

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +14 more
Locations
  • Stamford Hospital/Bennett Cancer Center Stamford, Connecticut, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Lifespan Cancer Institute Providence, Rhode Island, United States
View Trial Details
Active, not recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748

Conditions
AML/MDS, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, +33 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • TriStar Bone Marrow Transplant Nashville, Tennessee, United States
View Trial Details
Active, not recruiting

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

NCT04155749

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Advanced Cellular Therapeutics Facility, DCAM 0800A Chicago, Illinois, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Froedtert Hospital/Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Active, not recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024

Conditions
Blood Protein Disorders, COVID-19, COVID-19 Infection, +30 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Johns Hopkins University Baltimore, Maryland, United States
  • U Mass Chan Medical School Worcester, Massachusetts, United States
  • SUNY-Stony Brook Stony Brook, New York, United States
View Trial Details
Active, not recruiting

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

NCT05396885

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • HonorHealth Cancer Transplant Institute Scottsdale, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 18 locations
View Trial Details

Related conditions